Profile data is unavailable for this security.
About the company
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
- Revenue in USD (TTM)255.72k
- Net income in USD-4.40m
- Incorporated2011
- Employees0.00
- LocationEndonovo Therapeutics Inc6320 Canoga Avenue, 15Th FloorWOODLAND HILLS 91367United StatesUSA
- Phone+1 (800) 489-4774
- Fax+1 (818) 230-9899
- Websitehttps://endonovo.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Many Bright Ideas Technologies Inc | 0.00 | -50.91k | 167.27k | -- | -- | -- | -- | -- | -0.004 | -0.004 | 0.00 | -0.0166 | 0.00 | -- | -- | -- | -741.19 | -272.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 6.88 | -- | -- | -- |
| CNBX Pharmaceuticals Inc | 0.00 | -393.35k | 174.15k | 1.00 | -- | -- | -- | -- | -0.0043 | -0.0043 | 0.00 | -0.0034 | 0.00 | -- | -- | 0.00 | -2,350.46 | -210.08 | -- | -- | -- | -- | -- | -2,154.06 | -- | -3.16 | -- | -- | -100.00 | -- | 54.84 | -- | -- | -- |
| Endonovo Therapeutics Inc | 255.72k | -4.40m | 180.76k | 0.00 | -- | -- | -- | 0.7069 | -0.0652 | -0.0652 | 0.0003 | -0.072 | 0.2256 | -- | -- | -- | -388.54 | -303.26 | -- | -- | 96.21 | 74.38 | -1,722.26 | -5,956.27 | -- | -1.38 | -- | -- | 85.15 | -- | -495.02 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Family CFO, Inc.as of 31 Dec 2025 | 60.00 | 0.00% |
| Hilltop Partners LLCas of 30 Sep 2025 | 0.00 | 0.00% |
